Sun Pharma receives USFDA approval for anti-cancer injection
The approval is to market generic version of Doxil injection, used in treating ovarian cancer in the US.
New Delhi, February 6, 2013: The Indian pharma company, Sun Pharma, has received the approval from the US health regulator, US Food and Drug Administration (USFDA) to market generic version of Doxil injection, used in treating ovarian cancer in the US. The Mumbai-based firm said in a statement that the subsidiary has received approval from USFDA for its Doxorubicin HCl Liposome Injection.
"This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC," the company said.
It is worth noting here that Doxorubicin HCl liposome injection is used in the treatment of patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.